2-(3-Bromobiphenyl)-3-yl-4,6-diphenyl-1,3,5-triazine | CAS:1606981-69-4

We serve 2-(3-Bromobiphenyl)-3-yl-4,6-diphenyl-1,3,5-triazine CAS:1606981-69-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-(3-Bromobiphenyl)-3-yl-4,6-diphenyl-1,3,5-triazine

Chemical Name:2-(3-Bromobiphenyl)-3-yl-4,6-diphenyl-1,3,5-triazine
CAS.NO:1606981-69-4
Synonyms:1,3,5-Triazine, 2-(3'-bromo[1,1'-biphenyl]-3-yl)-4,6-diphenyl-
2-(3'-Bromo[1,1'-biphenyl]-3-yl)-4,6-diphenyl-1,3,5-triazine
Molecular Formula:C27H18BrN3
Molecular Weight:464.35600
 
Specification:
Appearance:White powder
Assay:≥99.0%
 
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 2-(3-Bromobiphenyl)-3-yl-4,6-diphenyl-1,3,5-triazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(3-Bromo[1,1-biphenyl]-3-yl)-4,6-diphenyl-1,3,5-triazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(3-Bromo[1,1-biphenyl]-3-yl)-4,6-diphenyl-1,3,5-triazine Use and application,2-(3-Bromobiphenyl)-3-yl-4,6-diphenyl-1,3,5-triazine technical grade,usp/ep/jp grade.


Related News: Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.Trimethylsilyl trifluoromethanesulfonate manufacturer Here’s what Apple told CNN Business in a statement:5-hydroxymethyl Tolterodine supplier Here’s what Apple told CNN Business in a statement:2-Trifluoromethyl-5-bromopyridine vendor In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum.In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum.